Clinical Trials Logo

Basal Cell Carcinoma clinical trials

View clinical trials related to Basal Cell Carcinoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06046144 Completed - Melanoma Clinical Trials

Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors

Micro3
Start date: November 2, 2022
Phase:
Study type: Observational

Reflectance confocal microscopy (RCM) is the reference in vivo imaging technique for identifying malignant melanocytic tumors prior to surgical excision. However, it is not widely used due to its high cost and highly technical and time-consuming nature. In addition to RCM, we currently use 2 less expensive dermatoscopes that also allow in vivo diagnosis: super-high magnification dermoscopy (D400) and Fluorescence-Advanced videodermatoscopy (FAV).

NCT ID: NCT05853315 Completed - Clinical trials for Basal Cell Carcinoma

BCC Excision Revisited

Start date: November 12, 2019
Phase:
Study type: Observational

To readdress basal cell carcinoma (BCC) in the periocular region to prove histologically controlled surgical treatment efficacy and to identify high-risk characteristics.

NCT ID: NCT05634421 Completed - Clinical trials for Basal Cell Carcinoma

Training Health Care Professional in Detecting BCC on OCT Using E-learning and CUSUM-analysis

Start date: December 1, 2022
Phase:
Study type: Observational

In this study, various health care professionals will follow an E-learning module in which BCC detection on OCT is explained. Thereafter, the participants will test their skill by assessing OCT-scans. Their performance will be monitored using cumulative-sum analysis. After completion, newly trained OCT assessors will test their diagnostic accuracy for BCC detection on OCT in a exploratory study. The trainability, amount of required training and diagnostic accuracy will be compared between dermatologist and non-dermatologists.

NCT ID: NCT05608902 Completed - Clinical trials for Basal Cell Carcinoma

Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)

DOCTOBA
Start date: September 6, 2022
Phase:
Study type: Observational

Basal cell carcinoma (BCC) are the most frequent skin cancers. Their incidence is constantly increasing. BCC diagnosis is first clinically suspected and then confirmed following histological examination of either a skin biopsy or the excisional specimen. Surgery is the first-line treatment and some procedures (notably Mohs surgery) require extemporaneous histological analysis of the edges to ensure a complete excision. Such on-site histopathological examination can be time consuming and associated with decreased sensitivity. Skin imaging techniques have already been tested to overcome these limitations and seem promising. Although some of them - such as confocal microscopy - are already even used in vivo, there is to date no report of the use of full-field optical coherence tomography for the diagnosis of BCC. The DOCTOBA study intends to describe direct histopathological examination of fresh skin biopsy or excisional specimen with dynamic full-field optical coherence tomography.

NCT ID: NCT05581342 Completed - Clinical trials for Basal Cell Carcinoma

Added Value of OCT for Diagnosing Recurrent BCC After Non-invasive Treatment

TOBI
Start date: January 15, 2021
Phase: N/A
Study type: Interventional

Superficial basal cell carcinoma (sBCC) can be treated non-invasively, but follow-up is necessary because lesions can reoccur. This study aims to evaluate the additional value of optical coherence tomography (OCT) for the detection of recurrent BCC lesions, that may remain unrecognized by clinical and dermoscopic examination (CDE). This study compared the diagnostic accuracy of CDE and CDE combined with OCT for detection of recurrent basal cell carcinoma (BCC) after non-invasive treatment of sBCC.

NCT ID: NCT05126173 Completed - Clinical trials for Squamous Cell Carcinoma

DERM US and EU Validation Study

Start date: March 15, 2022
Phase:
Study type: Observational

This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the US and European population.

NCT ID: NCT05077033 Completed - Clinical trials for Basal Cell Carcinoma

Intratumoral phIL12 GET

SmartGeneH&N
Start date: September 28, 2021
Phase: Phase 1
Study type: Interventional

Electroporation provides non-viral gene delivery method for plasmid DNA. Its clinical application was already proven in preclinical and in clinical trial in treatment of melanoma skin metastases with plasmid coding IL-12, in USA. Intratumoral gene transfer of plasmid coding for IL-12 has proven safe end effective, having good local tumour control and some evidence indicates on abscopal effect. The EU directives recommend the use of plasmids without the gene for antibiotic resistance. For this purpose we constructed plasmid coding for IL-12 in accordance with the EU regulatory requirements. In the proposed study we intend to study the safety and tolerability of the constructed plasmid, phIL12, in treatment of basal cell carcinomas in patients with operable tumors in head and neck region. The study is designed as exploratory, dose escalating with the aim to determine the dose of plasmid that produces IL-12 expression in the tumours with best biological activity, infiltration of the immune cells and no toxicity.

NCT ID: NCT04969419 Completed - Melanoma (Skin) Clinical Trials

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Start date: June 18, 2021
Phase:
Study type: Observational

This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.

NCT ID: NCT04936932 Completed - Clinical trials for Basal Cell Carcinoma

Laser Treatment of Basal Cell Carcinoma

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Laser treatment of Basal cell carcinoma

NCT ID: NCT04925713 Completed - Clinical trials for Basal Cell Carcinoma

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

Start date: June 10, 2021
Phase: Phase 1
Study type: Interventional

One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..